An open label, observational, practice based, non-comparative, multicenter, prospective, active surveillance to evaluate the safety and efficacy of theoasthalin/theoasthalin forte tablet in patients with reversible airflow obstruction associated with asthma and other chronic lung diseases

Cipla Ltd0 个研究点目标入组 168 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. A written, signed, dated and ethics committee approved informed consent form (data sharing consent) from Patients and/or legally acceptable representatives
•2. Either male or female of age between 18 years and 60 years
•3. Patients with reversible airflow obstruction associated with asthma and other chronic lung diseases suitable to receive either theoasthalin/theoasthalin forte tablets.

•1. Patients with hypersensitivity to study drugs.
•2. Patients with pregnancy or lactation.
•3. Patients with Active peptic ulcer disease.
•4. Patients with Seizure disorders.
•5. Patients with Cardiac arrhythmias.
•6. Concurrent diseases such as Acute pulmonary edema, Congestive heart failure, Cor pulmonale, Fever; Ã¢â?°Â¥102 F for 24 hours or more; or lesser temperature elevations for longer periods, Hypothyroidism, Hyperthyroidism, Liver disease; cirrhosis, acute hepatitis, Sepsis with multi-organ failure, shock.
•7. Patients on beta-blocking drugs.
•8. Patients unsuitable for study as per InvestigatorÃ¢â?¬•s discretion.
•9. Participated in clinical trial 30 days prior to screening.

发起方